Side-by-side comparison of AI visibility scores, market position, and capabilities
$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.
ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.